Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

about

Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.

P2860

Q33710807-0D524D29-00E2-4CDE-8922-104B531D95EA

P2860

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

Item

http://www.wikidata.org/entity/Q40118761

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

@en

type

Item

label

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

@en

prefLabel

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

@en

P1476

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

@en

P2093

Antonio Cozzio

http://www.w3.org/2001/XMLSchema#string

Astrid Sönnichsen

http://www.w3.org/2001/XMLSchema#string

Emmanuella Guenova

http://www.w3.org/2001/XMLSchema#string

Ieva Saulite

http://www.w3.org/2001/XMLSchema#string

Ignatova Desislava

http://www.w3.org/2001/XMLSchema#string

Johanna Mangana

http://www.w3.org/2001/XMLSchema#string

Katrin Kerl

http://www.w3.org/2001/XMLSchema#string

Tarun Mehra

http://www.w3.org/2001/XMLSchema#string

Ulf Petrausch

http://www.w3.org/2001/XMLSchema#string

Wolfram Hoetzenecker

http://www.w3.org/2001/XMLSchema#string

P2860

Schnitzler's syndrome: lessons from 281 cases

The Schnitzler syndrome. Four new cases and review of the literature.

The Schnitzler syndrome.

Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment.

Blocking IL-1 in systemic inflammation

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature.

Schnitzler's syndrome: diagnosis, treatment, and follow-up.

Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study.

Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.

P304

436-438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/09546634.2015.1136048

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Schmid-Grendelmeier

Emmanuella Guenova

P577

2016-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26864191

http://www.w3.org/2001/XMLSchema#string

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

about

P2860

P2860

Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698